ChAd-MVA.HIVconsv-BCN01
Status:Completed
Phase:I
Principal Investigator(s):Beatriz Mothe, MD,PhD & Josep Maria Miró, MD,PhD
Objective:Evaluate the safety and immunogenicity of ChAdV63.HIVcons and MVA.HIVconsv HIV-1 vaccines.
Prevention Option(s):Therapeutic Vaccines
Study Design:Controlled, Non-randomized
Arms and Assigned Interventions
DescriptionStart antiretroviral treatment raltegravir + tenofovir/emtricitabine.
ChAdV63.HIVcons (5x10^10 vp) and MVA.HIVconsv (2x10^8 pfu) HIV-1 vaccines.
Vaccines: 0-24 week prime/boost regimen
Mode of DeliveryIntramuscular
ARMs
DescriptionStart antiretroviral treatment raltegravir + tenofovir/emtricitabine.
ChAdV63.HIVcons (5x10^10 vp) and MVA.HIVconsv (2x10^8 pfu) HIV-1 vaccines
HIV-1 vaccines: 0-8 week prime/boost regimen
Mode of DeliveryIntramuscular
ARMs
DescriptionStart antiretroviral treatment raltegravir + tenofovir/emtricitabine. Follow-up as in Arm A.
Mode of Delivery
ARMs
DescriptionStart antiretroviral treatment raltegravir + tenofovir/emtricitabine. Follow-up as in Arm B.
Mode of Delivery
ARMs
Official Code:
NCT01712425
Trial Sponsors:
Beatriz Mothe MD PhD, Josep Maria Miró MD PhD
Start Date
End Date
October 31, 2012
April 30, 2015
Enrollment:48
Age range:
18 Years ↔
60 Years
Population:Cisgender Men, Cisgender Women, People Living with HIV